[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"headache-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:headache-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,58,84,108,135,187,209,239,278,295,327,353,381,408,435,459,478],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100417438","mind-body-balance-for-pediatric-migraine-100417438",false,"NCT04715685","Mind Body Balance for Pediatric Migraine","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura or chronic migraine that meets the International Classification of Headache Disorders(ICHD) criteria\n* Frequency: Headache frequency based upon prospective headache diary of 28 days must be ≥ 4 and ≤ 28.\n* PedMIDAS: PedMIDAS Disability Score \\> 4, indicating at least mild disruption in daily activities and \\\u003C 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Use of one or more of the following prescribed nutraceuticals and\u002For preventive anti-migraine medications at the time or randomization or be on a stable dose of one or more of the following throughout the 12 weeks of the study \\[Vitamin B2 (Riboflavin), Co-Q 10 (Coenzyme Q10), Magnesium (Mg), Vitamin D2 or D3 (Erocalciferol\u002FCholecalciferol), Depakote (Divalproate), Inderal (Propanerol), Elavil ((Amitripyline), Topamax (Topiramate), Periactin (Cyproheptadine)\\]\n* Language: English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Continuous migraine defined as unrelenting headache for a 28 day period\n* Must agree not to take non-specific acute medication, such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications, such as triptans, more than 6 times per month (to prevent medication overuse headache)\n* PedMIDAS Disability Score \\> 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Youth who are pregnant, or those who are sexually active and not using a medically accepted form of contraception (barrier or hormonal methods)\n* Present severe psychiatric disease, alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) or other circumstances, that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study","ALL","10 Years","17 Years",{"count":19,"type":20},260,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.",[26,27,28,29,30,31,32,33],"Headache","Headache Disorders","Headache, Migraine","Migraine","Migraine Disorders","Migraine With Aura","Migraine Without Aura","Chronic Migraine",[35,36,37,38,39,40,41,42,43,44],"headache","migraine","cognitive behavioral therapy","pediatrics","mind body intervention","diaphragmatic breathing","progressive muscle relaxation","imagery","relaxation","biofeedback","RECRUITING","2026-06-14",{"date":48,"type":49},"2026-06-16","ACTUAL",{"date":51,"type":49},"2021-03-09",{"date":53,"type":20},"2026-11-30",{"name":55,"class":56},"Children's Hospital Medical Center, Cincinnati","OTHER",2,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100529169","sequential-multiple-assignment-double-randomized-preference-migraine-behavioral-trial-100529169","NCT06170281","Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial","A Feasibility Clinical Trial Assessing Patient Preference, Optimum Combinations and Sequences of a Multicomponent, Virtually-Delivered Migraine Behavioral Intervention","SMARTMig","Inclusion Criteria:\n\n* have chronic migraine for a minimum of 1-year\n* aged 18 years and older\n\nExclusion Criteria:\n\n* secondary headache disorders\n* children younger than 18 years old","18 Years",{"count":68,"type":20},24,[23],"This study will unpack the behavioral intervention for migraine and determine the optimum combinations. In addition, the study will test preference and self-selection effects during the trial.",[29,26,33,27],[36,35,73],"behavioral intervention","NOT_YET_RECRUITING","2026-06-12",{"date":48,"type":49},{"date":78,"type":20},"2026-12",{"date":80,"type":20},"2028-12-01",{"name":82,"class":56},"Mayo Clinic",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":83},"100471142","determining-the-utility-of-a-behavioral-intervention-in-chronic-migraine-100471142","NCT05415020","Determining the Utility of a Behavioral Intervention in Chronic Migraine","Feasibility, Acceptability, and Pilot Testing of a Behavioral Intervention for Chronic Migraine","RLB","Inclusion Criteria:\n\n* have chronic migraine for a minimum of 1-year\n* aged 18 years and older\n\nExclusion Criteria:\n\n* other headache disorders including secondary headache disorders\n* children younger than 18 years old\n* current pregnancy",{"count":93,"type":20},60,[23],"This proposal will involve a pilot study to evaluate the feasibility, acceptability, and outcomes of a lifestyle behavior protocol in managing chronic migraine. Additionally, the proposal will investigate biomolecules that are uniquely involved in chronic migraine patients who respond to the protocol. Successful completion of this proposal will inform the design of a future full-scale behavioral clinical trial to control chronic migraine.",[29,26,30,33,97,27],"Lifestyle Factors",[30,26,99],"Lifestyle","2026-06-04",{"date":102,"type":49},"2026-06-08",{"date":104,"type":49},"2022-06-29",{"date":106,"type":20},"2027-07-31",{"name":82,"class":56},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":57},"100598439","new-methods-for-evaluating-preventive-migraine-treatment-100598439","NCT07071506","New Methods for Evaluating Preventive Migraine Treatment","Inclusion Criteria:\n\n1. Adults (18-65 years)\n2. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria\n3. Known chronic migraine (headache occurring ≥ 15 days per month for \\> 3 months, which on at least 8 days per month has the features of migraine headache) diagnosed before age 65\n4. Eligibility for preventive migraine treatment\n5. Ability to speak and read Danish\n\nExclusion Criteria:\n\n1. Use of onabotulinumtoxinA as preventive migraine treatment during the 4 months before inclusion\n2. Use of other preventive migraine treatment except CGRP antagonists (However, participants are allowed to be on two stable preventive medication (antidepressant, calcium channel blockers, beta blockers or antiepileptic)- 2 months prior to inclusion until end of study), devices for migraine prevention such as transcranial magnetic stimulation and use of nerve blocks 3 months prior to inclusion\n3. Use of opioid or barbiturate medications in the last four weeks before inclusion\n4. Secondary headache disorders including medication overuse headache\n5. Severe psychiatric, vascular disease, or known liver disease\n6. Alcohol abuse or substance abuse\n7. Current or planned pregnancy and lactation","65 Years",{"count":93,"type":20},[23],"The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.",[29,119,27,120],"Migraine With or Without Aura","Chronic Migraine, Headache",[26,122,123,124,125],"Chronic migraine","Balanced placebo design","Treatment effects","Adverse events","2026-05-18",{"date":128,"type":49},"2026-05-19",{"date":130,"type":49},"2025-06-19",{"date":132,"type":20},"2028-09",{"name":134,"class":56},"University of Aarhus",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":142,"minAge":66,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":159,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":83},"100571149","aerobic-exercise-and-its-impact-on-sensory-musculoskeletal-and-psychosocial-aspects-in-migraine-100571149","NCT06716489","Aerobic Exercise and Its Impact on Sensory, Musculoskeletal, and Psychosocial Aspects in Migraine","Influence of Aerobic Exercise on Sensory Perception, Musculoskeletal and Psychosocial Alterations in Patients With Migraine","Inclusion Criteria:\n\n* Women aged between 18 and 48 years.\n* Diagnosed with migraine by an experienced neurologist specialized in headaches, following the criteria of the International Classification of Headache Disorders (ICHD).\n* Frequency of headache between 3 and 8 days per month, to ensure adherence to the treatment.\n\nExclusion Criteria:\n\n* Presence of any other type of concurrent headache.\n* Medical conditions affecting sensitivity and autonomic modulation, such as peripheral neuropathies, autonomic disorders, severe neurological diseases, and others.\n* Conditions that prevent physical activity, such as severe musculoskeletal injuries, cardiovascular diseases, or related conditions.\n* Premature ovarian failure.\n* Regular physical exercise in the past year.\n* Body Mass Index (BMI) above 30.0.\n* Smokers or individuals using drugs that interfere with sensitivity and cardiac modulation (e.g., beta-blockers).\n* Abuse of abortive medications.","FEMALE","48 Years",{"count":145,"type":20},100,[23],"Migraine is a neurological disorder associated with high levels of disability and changes in sensory processing, musculoskeletal function, and psychosocial factors. Aerobic exercise is a low-cost, non-pharmacological strategy that has shown potential benefits for migraine management, but its effects on sensory perception and musculoskeletal function are not yet fully understood.\n\nThis randomized controlled trial will investigate the effects of a supervised aerobic exercise program combined with pain neuroscience education compared with an active control condition in women aged 18 to 48 years diagnosed with migraine. Participants will be randomly allocated to either an intervention group, which will perform supervised aerobic exercise three times per week for 16 weeks and receive one session of pain neuroscience education, or a control group, which will receive recommendations for unsupervised physical activity at home.\n\nOutcomes related to migraine-related disability, self-reported symptoms, sensory sensitivity, and musculoskeletal function will be assessed at baseline and after the intervention period. Questionnaires will also be collected at a 6-month follow-up. The results of this study may contribute to the development of accessible and low-risk non-pharmacological treatment strategies for people with migraine.",[29,149,150,151,26,152,27,153,154,155,156,157,158],"Migraine Disease","Migraine Disorder","Migraine Disorders, Brain","Headache (Migraine)","Headache Disorders, Primary","Aerobic Exercise","Pain Management","Sensory Disorders","Psychosocial Factors","Quality of Life",[36,160,161,162,35,163,164,165,166,167,168,157,169,170,171,172,173,174,175,176,177],"aerobic exercise","sensory perception","exercise","disability","musculoeskeletal alterations","quality of life","neck pain","cervical pain","Sensory Thresholds","Physical Fitness","Exercise Intervention","Central Sensitization","Physical Therapy","Migraine Management","Non-pharmacological Treatment","Clinical Trial","Headache Relief","sensitization","2026-04-27",{"date":180,"type":49},"2026-04-28",{"date":182,"type":49},"2026-03-03",{"date":184,"type":20},"2028-11-30",{"name":186,"class":56},"University of Sao Paulo",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},"100507610","responding-with-evidence-and-access-for-childhood-headaches-100507610","NCT05889624","Responding With Evidence and Access for Childhood Headaches","Cognitive Behavioral Therapy Via Telehealth + Amitriptyline Compared to Cognitive Behavioral Therapy Via Telehealth: Pediatric Migraine Prevention (Responding With Evidence and Access for Childhood Headaches)","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura that meets the International Classification of Headache Disorders (ICHD) criteria 5 or presentation of continuous headache that includes migranous episodes based upon headache history obtained by site PI or designee. (includes presentation with or without medication overuse headache as well)\n* Headache Frequency: 4 or more headache days based upon prospective headache diary of 28 days prior to randomization\n* Amitriptyline Eligible: Site PI or medical staff determined participant to be eligible for clinical prescription of amitriptyline as a preventive treatment for migraine\n* English fluency: Able to complete the study visits and questionnaires in English\n\nExclusion Criteria:\n\n* Current treatment includes amitriptyline and\u002For CBT specific to headache care\n* Current prescribed preventive antimigraine medication within a period equivalent to \\\u003C 5 half-lives of that medication before entering the baseline phase\n* Current treatment with onabotulinumtoxinA (Botox) or CGRP-based monoclonal antibody medications for migraine prevention\n* Youth who are pregnant\n* Report of current or ongoing suicidal thoughts. Suicide attempt within the past six months. History of bipolar disorder, prolonged QT, or pre-existing significant constipation or gastroparesis\n* Any and all other diagnoses or conditions which, in the opinion of the site investigator, would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the participant",{"count":195,"type":20},400,[23],"This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will be compared to CBT via telehealth alone.",[26,27,28,29,30,31,32,33],[35,36,37,38,40,41,42,43,44],"2026-03-04",{"date":202,"type":49},"2026-03-06",{"date":204,"type":49},"2023-08-22",{"date":206,"type":20},"2027-12-31",{"name":55,"class":56},15,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":15,"minAge":216,"maxAge":17,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":83},"100625205","migrafit-evaluating-a-group-therapy-program-combining-physical-activity-progressive-muscle-relaxation-and-psychoeducation-for-adolescents-with-migraine-100625205","NCT07419607","MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducation for Adolescents With Migraine","MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducation for Adolescents With Migraine - Study Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed migraine as defined by ICHD-3 (International Classification of Headache Disorders, 3rd edition)\n* Age: 13-17 years\n* Place of residence within a 35-kilometer radius of the study site, except for children who live outside of this radius but commute close to the study site daily due to school or work attendance\n\nExclusion Criteria:\n\n* Intake of continuous prophylactic medication for migraine\n* Any change in migraine medication within the past 4 weeks\n* Psychiatric or somatic comorbidities which could interfere with participation in a weekly group therapy that includes physical activity","13 Years",{"count":218,"type":20},30,[23],"Background: Migraine is a headache disorder highly prevalent in children and adolescents. It significantly affects academic performance and quality of life. A conservative approach to pharmacological prophylaxis for pediatric patients persists in clinical practice, as potential risks must be carefully weighed against the benefits for each individual patient. Non-pharmacological interventions, including physical activity, progressive muscle relaxation (PMR) and psychoeducation have shown promising effects individually but demand a high level of patient motivation. This study protocol creates the foundation to evaluate a novel group therapy program combining high-intensity interval training (HIIT), PMR, and psychoeducation tailored for children and adolescents with migraine.\n\nMethods: This single-centre, open-label, randomized controlled trial will enrol 80 participants aged 13 to 17 years and diagnosed with migraine according to ICHD-3 criteria. Participants are randomized 1:1 into an intervention and control group. The intervention group will receive a 18-week, once-weekly 65-minute group therapy (comprising HIIT and PMR) plus two sessions of psychoeducation. The control group receives no intervention. Primary outcomes are changes in migraine frequency, duration, intensity and acute medication use, assessed through standardized headache diaries before and after the intervention. Secondary outcomes include changes in migraine-related disability (PedMIDAS questionnaire), exploratory analysis of physical activity patterns in a subgroup and a patient-centered evaluation of the intervention's feasibility and perceived effectiveness.\n\nDiscussion: This trial will provide evidence on the effectiveness and feasibility of a structured, time-efficient, multimodal group therapy intervention for pediatric migraine. By combining physical and psychological strategies within a supportive group setting, the program aims to overcome key limitations of adherence and offer a non-pharmacological treatment alternative. If successful, the intervention is intended to be incorporated into routine outpatient care for pediatric migraine at the Medical University of Innsbruck.",[29,27,222],"Pediatric Migraine",[29,224,225,226,227,41,228,229],"children","adolescents","physical activity","high intensity interval training","psychoeducation","randomized controlled trial","2026-02-11",{"date":232,"type":49},"2026-02-19",{"date":234,"type":20},"2026-03-01",{"date":236,"type":20},"2027-06-30",{"name":238,"class":56},"Medical University Innsbruck",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":114,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":267,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":83},"100619142","hypersensitivity-to-amylin-in-post-traumatic-headache-100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache",{"count":247,"type":20},21,[23],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[251,252,27,253,254,255,256,257,258,259,260,261,262,263,264,265,266],"Headache Disorders, Secondary","Brain Diseases","Nervous System Diseases","Central Nervous System Diseases","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Post-Traumatic Headache","Pain","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Peptides","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[268,259,265],"Post-traumatic headache","2026-01-05",{"date":271,"type":49},"2026-01-14",{"date":273,"type":20},"2026-02",{"date":275,"type":20},"2028-12",{"name":277,"class":56},"Danish Headache Center",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":114,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":292,"leadSponsor":294,"locationsCount":83},"100619143","amylin-induced-migraine-attacks-without-aura-100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":247,"type":20},[23],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[153,27,252,253,254,255,256,257,30,26,259,260,261,262,263,264,265,266],[29,26,259,265],{"date":271,"type":49},{"date":273,"type":20},{"date":293,"type":20},"2028-10-30",{"name":277,"class":56},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":83},"100616584","efficacy-of-scalp-block-in-managing-post-subarachnoid-hemorrhage-headache-in-critically-ill-patients-a-single-centre-randomized-controlled-trial-100616584","NCT07307508","Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial","SAH-BLOCK","Inclusion Criteria:\n\n* All adults \\> 18 years who are admitted to the Surgical Intensive Care Unit (SICU) with a confirmed diagnosis of aneurysmal subarachnoid hemorrhage, undergoing endovascular treatment of the aneurysm (coiling\u002Fflow diversion).\n\nExclusion Criteria:\n\n1. Patients with aSAH undergoing surgical craniotomy and aneurysmal clipping.\n2. Non-aneurysmal subarachnoid or other intracranial hemorrhage forms (e.g., Intracerebral hemorrhage).\n3. SICU admission Glasgow Coma Scale (GCS) of 13 or lower.\n4. WFNS Score 4 \u002F 5 or requiring mechanical ventilation for more than 24 hrs.\n5. Patients with known allergy to local anesthetics.\n6. Admission to ICU \\> 7 days after hemorrhage.\n7. Patients with a documented bleeding disorder.\n8. Patients with a history of chronic headache disorder or migraine.\n9. Pregnancy",{"count":303,"type":20},22,[23],"Subarachnoid hemorrhage (SAH) is a devastating neurological disorder associated with significant mortality and morbidity rates, arising not just from the hemorrhage itself but also because of the catastrophic multisystem sequelae that can accompany the condition.\n\nRupture of an intracranial aneurysm accounts for up to 85% of instances of SAH, occurring in approximately 3 to 25 people per 100,000 annually in most populations. Treatment of aneurysmal SAH (aSAH) includes prevention of re-bleeding, evacuation of space-occupying hematomas, management of hydrocephalus, and prevention of secondary cerebral insult. Severe headache is the predominant characteristic symptom of aSAH, developing almost instantaneously at ictus in 50% of cases and continuing into the first days. Its severity has a variety of physiological and psychological effects on the patient. Scalp blocks have been suggested to alleviate this headache in case series. However, there is no strong evidence supporting this intervention. In this study, we aim to assess the impact of scalp blocks on headache reduction in patients undergoing endovascular treatment of an aneurysm (coiling or flow diversion) with aneurysmal subarachnoid bleeding.",[307,27],"Aneurysmal Subarachnoid Hemorrhage (aSAH)",[309,310,311,312,313,314,315,316],"Subarachnoid Hemorrhage Headache","Aneurysmal Subarachnoid Hemorrhage","Cerebral Aneurysm","SAH-associated headache","Scalp Block","Levobupivacaine","Opioid Consumption","Neurocritical Care","2025-12-14",{"date":319,"type":49},"2025-12-29",{"date":321,"type":49},"2025-10-22",{"date":323,"type":20},"2026-12-30",{"name":325,"class":326},"Hamad Medical Corporation","INDUSTRY",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":338,"phases":4,"briefSummary":339,"conditions":340,"keywords":342,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":83},"100613605","personological-structure-cognitive-functions-and-central-sensitization-in-headache-100613605","NCT07268768","PERSONOLOGICAL STRUCTURE, COGNITIVE FUNCTIONS AND CENTRAL SENSITIZATION IN HEADACHE","Personological Structure, Cognitive Functions and Central Sensitization in Headache: Obstacles and Resources in the Treatment of Chronic and Episodic Headache.","AURA","Inclusion Criteria:\n\n* Age between 18 and 60 years;\n* Diagnosis of chronic or episodic headache;\n* Patients attending the Headache Outpatient Clinic.\n\nExclusion Criteria:\n\n* Presence of severe psychiatric and neurological disorders;\n* Presence of oncological diseases in terminal stage","60 Years",{"count":337,"type":20},64,"OBSERVATIONAL","Headache, in its episodic and chronic forms, cannot be considered solely as an isolated neurological symptom, but as a complex condition of a bio-psycho-social nature. While in the episodic form the painful episodes occur intermittently and have a variable impact on daily life, in the chronic form the disease evolves towards persistent pain, with more significant consequences on personal, social and work functioning. The following study protocol aims to investigate in an integrated manner the neurological, cognitive and psychological mechanisms involved in headache, with particular attention to the differences between episodic and chronic forms. The main objective is to assess the neuropsychological profiles and pain response of patients, monitoring their evolution over a period of approximately six months, considering the impact of central sensitisation, personality structure and any psychopathological comorbidities on pain management and treatment adherence. The protocol adopts a multidimensional approach aimed at optimising therapeutic efficacy and improving patients' quality of life, preventing progression to chronicity.",[341,27],"Chronic and Episodic Headache",[343],"chronic migraine; central sensitization; cognitive impairment; personality disorders; treatment adherence; anxiety; depression;","2025-12-05",{"date":346,"type":49},"2025-12-08",{"date":348,"type":49},"2025-11-20",{"date":350,"type":20},"2028-11-20",{"name":352,"class":56},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":21,"phases":361,"briefSummary":362,"conditions":363,"keywords":367,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":83},"100595520","effects-of-online-mindfulness-therapy-on-pain-and-stress-in-adults-with-chronic-migraine-and-adverse-childhood-experiences-100595520","NCT07033520","Effects of Online Mindfulness Therapy on Pain and Stress in Adults With Chronic Migraine and Adverse Childhood Experiences","Effects of Online Mindfulness-Based Cognitive Therapy on Pain, Stress-Related Symptoms, and Functionality in Adults With Chronic Migraine and Adverse Childhood Experiences at the International Hospital of Colombia","Inclusion Criteria:\n\n* Male and female patients aged 18 years or older with a diagnosis of chronic migraine according to the International Classification of Headache Disorders (ICHD-3), based on diagnostic criteria updated through 2018.\n* Willingness to participate in online sessions from 6:00 PM to 8:00 PM on the scheduled day of the intervention.\n* Male and female patients with a score of 4 or higher on the Adverse Childhood Experiences Questionnaire.\n* Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Visual, auditory, cognitive, or functional limitations that prevent understanding of therapeutic activities or the ability to perform home tasks.\n* Presence of systemic inflammatory disorders, including rheumatic and autoimmune diseases.\n* Active malignancy.\n* Pregnancy or breastfeeding at the time of the study.\n* Pre-existing neurological conditions (e.g., epilepsy, neuromuscular disorders, metabolic diseases, among others).\n* Central nervous system tumors.\n* Diagnosis of terminal illnesses that prevent follow-up over time.",{"count":93,"type":20},[23],"This study aims to evaluate the effectiveness of an online Mindfulness-Based Cognitive Therapy (MBCT) program in reducing pain, stress-related symptoms, and improving functionality in adults with chronic migraine and a history of adverse childhood experiences (ACE). Participants will be randomly assigned to either the MBCT intervention group or a control group. The intervention is delivered entirely online over eight weeks. The study hypothesizes that MBCT will result in significant improvements in pain perception and stress-related symptoms compared to the control condition.",[33,364,365,366,27],"Adverse Childhood Experiences","Depression","Anxiety",[368,369,370,259,26,371,29,372],"Mindfulness-Based Cognitive Therapy","MBCT","Trauma","Online Psychological Intervention","Stress-Related Disorders","2025-06-23",{"date":375,"type":49},"2025-06-26",{"date":377,"type":20},"2025-07-01",{"date":348,"type":20},{"name":380,"class":56},"Fundación Cardiovascular de Colombia",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":114,"enrollmentInfo":388,"targetDuration":4,"studyType":21,"phases":390,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":83},"100374131","phase-3-idebenone-for-the-preventive-treatment-of-migraine-100374131","NCT04151472","Idebenone for the Preventive Treatment of Migraine","A Randomized, Double-blinded, Placebo-controlled Trial of Idebenone in the Prevention of Episodic Migraine","Inclusion Criteria:\n\n1. Clinical diagnosis of episodic migraine.\n2. Patients (18-65 years) were eligible if they met International Headache Society (IHS) criteria for episodic migraine with\u002F without aura with a migraine history 1 year\n3. Two to eight attacks per month, 5 days\u002Fmonth of interval headaches.\n4. No over consumption of acute anti-migraine medication.\n5. No other prophylactic medication (washout 3 months).\n6. No serious organic or psychiatric disease.\n7. Only women with contraceptive protection.\n\nExclusion Criteria:\n\n1. Clinical diagnosis of chronic migraine.\n2. Subjects previously discontinued idebenone due to adverse events.\n3. Subjects are taking idebenone or had taken idebenone within 14 days prior to enrollment.\n4. Subjects with continuous headaches.",{"count":389,"type":20},180,[391],"PHASE3","Idebenone improves energy metabolism similarly to Coenzyme Q10, which is effective in migraine prophylaxis. The investigators compare idebenone (90 mg\u002Fday, 270 mg\u002Fday) and placebo in 180 migraine patients in a double-blind, randomized, placebo-controlled, multicenter trial to study whether Idebenone is superior to placebo in the prevention of episodic migraine with or without aura.",[30,27],[395,396,397,398],"Migraine Prophylaxis","Mitochondrial Dysfunction","Idebenone","Individualized Treatment","2025-05-12",{"date":401,"type":49},"2025-05-15",{"date":403,"type":49},"2021-12-08",{"date":405,"type":20},"2025-12-31",{"name":407,"class":56},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":21,"phases":418,"briefSummary":419,"conditions":420,"keywords":424,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":83},"100558080","can-a-specific-omt-protocol-influence-patient-pain-and-associated-analgesia-use-for-primary-headache-disorders-100558080","NCT06546462","Can a Specific OMT Protocol Influence Patient Pain and Associated Analgesia Use for Primary Headache Disorders?","Can a Specific OMT Protocol Influence Patient-reported Pain and Associated Analgesia Use for Primary Headache Disorders?","Inclusion Criteria:\n\n* 18 to 75 years of age\n* takes opioids or any other pain medication for headaches more than 10 times a month (including over the counter and prescription medications for headaches).\n* 3 months or greater history of headaches or migraines\n* Patient able to tolerate OMT based on osteopathic physician discretion and with consideration of absolute and relative contraindications to OMT\n\nExclusion Criteria:\n\n* current diagnosis of neoplasm\n* history of headache secondary to trauma or concussion\n* history of brain\u002Fcranial surgery, cerebral vascular events\u002Fdisease (e.g., stroke, Brain arteriovenous malformation (AVM), vertebral artery disease)\n* acute psychiatric diagnosis\n* pregnancy\n* history of substance use disorder","75 Years",{"count":417,"type":20},20,[23],"The purpose of this study is to see if osteopathic manipulation or light touch can reduce either or both frequency of headaches or use of pain medication. Osteopathic manipulative treatment (OMT) has been shown to help headache symptoms. The investigators like to see if regular OMT sessions can help reduce headache discomfort and also reduce use of pain medication like over-the-counter medications, migraine medications, and opioids. In this randomized controlled trial, a set sequence of OMT will be compared to light touch sham protocol. Investigators will compare participant responses to questionnaires that assess items including pain levels and reported pain medication use for the course of the study period to see if there are any shifts.",[27,26,421,422,423],"Analgesia","Opioid Use","Osteopathy",[425,426,26],"Osteopathic manipulative medicine","Osteopathic manipulative treatment","2025-03-12",{"date":429,"type":49},"2025-03-17",{"date":431,"type":20},"2025-04-08",{"date":405,"type":20},{"name":434,"class":56},"New York Institute of Technology",{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":15,"minAge":442,"maxAge":66,"enrollmentInfo":443,"targetDuration":444,"studyType":338,"phases":4,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":4},"100582818","prevalence-and-pattern-of-headache-in-pediatric-epilepsy-100582818","NCT06868251","Prevalence and Pattern of Headache in Pediatric Epilepsy","Prevalence and Pattern of Comorbid Headache in Pediatric Epilepsy Patients Attending Assiut University Children Hospital.","Inclusion Criteria:\n\n\\- pediatric epilepsy patients (5:18 years of age) who are mentally normal and can describe their symptoms.\n\n2\u002F Acceptance to participate in this study.\n\nExclusion Criteria:\n\n\\- \u002F Children who can't express their symptoms properly because of mental retardation, psychiatric illness or verbal disability.\n\n2\u002F Children or Parents who refused to participate in this study.","5 Years",{"count":93,"type":20},"1 Month","This study aims to determine the prevalence and characteristics of headaches in children with epilepsy, aged 5-18 years. Approximately 60 children will participate at Assiut University Children's Hospital. The research will involve medical history collection, physical and neurological exams, EEG review, and blood tests. The study seeks to improve understanding of the relationship between epilepsy and headaches in children, potentially leading to better treatment strategies. Participation is voluntary, and the risks are minimal.",[27,447],"Epilepsy",[449,35,450],"epilepsy","pediatric epilepsy","2025-03-07",{"date":453,"type":49},"2025-03-10",{"date":455,"type":20},"2025-05-01",{"date":323,"type":20},{"name":458,"class":56},"Assiut University",{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":15,"minAge":66,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":21,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":476,"locationsCount":83},"100519319","smartphone-use-restriction-as-treatment-of-primary-headache-100519319","NCT06041997","Smartphone Use Restriction as Treatment of Primary Headache","Smartphone Use Restriction as Treatment of Primary Headache: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Patients ≥18 years of age\n2. Diagnosis of primary headache as per the ICHD3Beta classification (\"ICHD-3 The International Classification of Headache Disorders 3rd Edition\" n.d.)\n3. Willing and consenting to participate in the study.\n\nExclusion Criteria:\n\n* 1\\. Secondary headaches 2. Not consenting for participation or follow up",{"count":93,"type":20},[23],"The goal of this clinical trial is to study smartphone use restriction as a treatment modality in patients of primary headache. The main question\\[s\\] it aims to answer are:\n\n1. In patients with primary headache, does restriction of smartphone use lead to reduced consumption of medications (acute, prophylaxis, either or both)?\n2. In patients with primary headache, does restriction of smartphone use lead to better responsiveness to medications (acute, prophylaxis, either or both)?\n3. Can reduction of smartphone duration be used as a non-pharmacological treatment of primary headache?\n4. In patients with primary headache, is the type of smartphone use (phone calls, internet browsing, watching screen) determinant of the severity of headache?\n5. Can we make an addiction score to predict which patient should be advised to limit smartphone use based on the above information?\n6. In patients with primary headache, does restriction of smartphone use led to improvement in headache severity (frequency, intensity, duration, one of them or all).\n\nThe smartphone users may further be classified into low and high smartphone users depending upon the smartphone addiction questionnaire (SAQ) (appendix 1) usage score. SUs with 0-1 score on the SAQ were further grouped into low SUs, and patients with score ≥1 were grouped into high SUs. To create a homogenous group, only patients with high SU will be randomized to standard treatment (Arm C) and intervention group (Arm D).\n\nParticipants will be asked about their smartphone usage, and if found eligible, there will be a run-in period of 4 weeks after which they will be randomized to the intervention (smartphone restriction) or comparison group (no restriction recommended)",[27],"2024-11-28",{"date":472,"type":49},"2024-12-02",{"date":474,"type":49},"2023-10-01",{"date":53,"type":20},{"name":477,"class":56},"All India Institute of Medical Sciences",{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":338,"phases":4,"briefSummary":488,"conditions":489,"keywords":490,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":83},"100317704","registrare-a-retro-prospective-registry-of-rare-primary-headaches-in-italian-tertiary-headache-centres-100317704","NCT03416114","RegistRare: a Retro-prospective Registry of Rare Primary Headaches in Italian Tertiary Headache Centres","RegistRare: a Retro-prospective Registry of Rare Primary Headaches in Italian Tertiary","RegistRare","Inclusion Criteria:\n\n* diagnosis of rare primary headaches (Part One, Chapter 3 and Chapter 4, ICHD-3 beta)\n* signed informed consent\n\nExclusion Criteria:\n\n* none",{"count":487,"type":20},3000,"Retro-prospective survey on specific and overall prevalence and incidence of rare primary headaches (Part One, Chapter 3 and Chapter 4, ICHD-3 beta) in patients referred to Italian Tertiary Headache Centres in a 3-year (May 1, 2014-April 30, 2017 - retrospective data) and annually (from May 1, 2017 - prospective data).",[27],[491,492],"rare headaches","epidemiology","2018-01-23",{"date":495,"type":49},"2018-01-30",{"date":497,"type":49},"2017-09-01",{"date":499,"type":20},"2027-08",{"name":501,"class":56},"Silvia Benemei"]